The FDA’s advisory committee delivered a contentious verdict on Capricor Therapeutics’ deramiocel for Duchenne muscular dystrophy, voting 9-3 against recommending approval. Panelists said the HOPE-3 trial evidence was “very fragile” and that the committee question left insufficient proof of substantial effectiveness, even as patients and unmet-need arguments were aired during the meeting.